Author

A. E. Muruato

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:benchmarking· 1 Organism:rat· 1

Frequent Co-Authors

P.-Y. Shi· 5 shared V. D. Menachery· 5 shared X. Xie· 4 shared C. R. Fontes-Garfias· 3 shared H. Xia· 3 shared J. Liu· 3 shared J. Zou· 3 shared P. Ren· 3 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

P.-Y. Shi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions

Y. Liu, X. Zhang, J. Liu, H. Xia, J. Zou, A. E. Muruato, S. Periasamy, J. A. Plante, N. E. Bopp, C. Kurhade, A. Bukreyev, P. Ren, T. Wang, V. D. Menachery, K. S. Plante, , P.-Y. Shi

This paper describes a live-attenuated SARS-CoV-2 vaccine candidate with deleted ORFs that shows reduced replication and attenuation in animal models, and reports its protective efficacy against wild-type virus challenge.

bioRxiv · Feb 14, 2022Microbiology

Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth

Z. Ku, X. Xie, J. Lin, P. Gao, A. E. Sahili, H. Su, Y. Liu, X. Ye, X. Li, X. Fan, B. C. Goh, W. Xiong, H. Boyd, A. E. Muruato, H. Deng, , Z. An

This study engineers bispecific antibodies against SARS-CoV-2, showing that one design outperforms a cocktail in neutralizing activity and breadth against variants.

bioRxiv · Feb 1, 2022 · PreprintMicrobiology

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

P.-Y. Shi, X. Xie, A. E. Muruato, X. Zhang, K. G. Lokugamage, C. R. Fontes-Garfias, J. Zou, J. Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.-T. K. Tseng, S. Makino, V. D. Menachery, J. P. Bilello

This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.

Nature Communications · Oct 15, 2020Peer-reviewedMicrobiology

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility

J. A. Plante, Y. Liu, J. Liu, H. Xia, B. A. Johnson, K. G. Lokugamage, X. Zhang, A. E. Muruato, J. Zou, C. R. Fontes-Garfias, D. Mirchandani, D. Scharton, J. P. Bilello, Z. Ku, Z. An, , P.-Y. Shi

This study shows the D614G mutation in SARS-CoV-2 increases viral replication and upper respiratory tract viral loads but does not reduce vaccine efficacy or antibody neutralization.

bioRxiv · Sep 1, 2020Microbiology

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

A. E. Muruato, C. R. Fontes-Garfias, P. Ren, M. A. Garcia-Blanco, V. D. Menachery, X. D. Xie, P.-Y. Shi

This paper develops a high-throughput fluorescence-based assay to measure SARS-CoV-2 neutralizing antibodies, showing comparable results to the gold standard plaque reduction neutralizing assay.

bioRxiv · May 21, 2020Microbiology